246 related articles for article (PubMed ID: 26407589)
1. Simultaneous Targeting of FcγRs and FcαRI Enhances Tumor Cell Killing.
Brandsma AM; Ten Broeke T; Nederend M; Meulenbroek LA; van Tetering G; Meyer S; Jansen JH; Beltrán Buitrago MA; Nagelkerke SQ; Németh I; Ubink R; Rouwendal G; Lohse S; Valerius T; Leusen JH; Boross P
Cancer Immunol Res; 2015 Dec; 3(12):1316-24. PubMed ID: 26407589
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
[TBL] [Abstract][Full Text] [Related]
3. IgA EGFR antibodies mediate tumour killing in vivo.
Boross P; Lohse S; Nederend M; Jansen JH; van Tetering G; Dechant M; Peipp M; Royle L; Liew LP; Boon L; van Rooijen N; Bleeker WK; Parren PW; van de Winkel JG; Valerius T; Leusen JH
EMBO Mol Med; 2013 Aug; 5(8):1213-26. PubMed ID: 23918228
[TBL] [Abstract][Full Text] [Related]
4. FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy.
Valerius T; Stockmeyer B; van Spriel AB; Graziano RF; van den Herik-Oudijk IE; Repp R; Deo YM; Lund J; Kalden JR; Gramatzki M; van de Winkel JG
Blood; 1997 Dec; 90(11):4485-92. PubMed ID: 9373259
[TBL] [Abstract][Full Text] [Related]
5. Augmented antibody-based anticancer therapeutics boost neutrophil cytotoxicity.
Heemskerk N; Gruijs M; Temming AR; Heineke MH; Gout DY; Hellingman T; Tuk CW; Winter PJ; Lissenberg-Thunnissen S; Bentlage AE; de Donatis M; Bögels M; Rösner T; Valerius T; Bakema JE; Vidarsson G; van Egmond M
J Clin Invest; 2021 Mar; 131(6):. PubMed ID: 33561014
[TBL] [Abstract][Full Text] [Related]
6. Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies.
Huls G; Heijnen IA; Cuomo E; van der Linden J; Boel E; van de Winkel JG; Logtenberg T
Cancer Res; 1999 Nov; 59(22):5778-84. PubMed ID: 10582699
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo.
Li B; Xu L; Tao F; Xie K; Wu Z; Li Y; Li J; Chen K; Pi C; Mendelsohn A; Larrick JW; Gu H; Fang J
Oncotarget; 2017 Jun; 8(24):39356-39366. PubMed ID: 28454118
[TBL] [Abstract][Full Text] [Related]
8. Potent Fc Receptor Signaling by IgA Leads to Superior Killing of Cancer Cells by Neutrophils Compared to IgG.
Brandsma AM; Bondza S; Evers M; Koutstaal R; Nederend M; Jansen JHM; Rösner T; Valerius T; Leusen JHW; Ten Broeke T
Front Immunol; 2019; 10():704. PubMed ID: 31031746
[TBL] [Abstract][Full Text] [Related]
9. IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47-SIRPα Checkpoint Inhibition.
Treffers LW; Ten Broeke T; Rösner T; Jansen JHM; van Houdt M; Kahle S; Schornagel K; Verkuijlen PJJH; Prins JM; Franke K; Kuijpers TW; van den Berg TK; Valerius T; Leusen JHW; Matlung HL
Cancer Immunol Res; 2020 Jan; 8(1):120-130. PubMed ID: 31690649
[TBL] [Abstract][Full Text] [Related]
10. IgA Targeting Human Immunodeficiency Virus-1 Envelope gp41 Triggers Antibody-Dependent Cellular Cytotoxicity Cross-Clade and Cooperates with gp41-Specific IgG to Increase Cell Lysis.
Duchemin M; Khamassi M; Xu L; Tudor D; Bomsel M
Front Immunol; 2018; 9():244. PubMed ID: 29651286
[TBL] [Abstract][Full Text] [Related]
11. Proteolytic single hinge cleavage of pertuzumab impairs its Fc effector function and antitumor activity in vitro and in vivo.
Hsiao HC; Fan X; Jordan RE; Zhang N; An Z
Breast Cancer Res; 2018 Jun; 20(1):43. PubMed ID: 29859099
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of polymorphonuclear cell-mediated tumor cell killing on simultaneous engagement of fcgammaRI (CD64) and fcalphaRI (CD89).
van Egmond M; van Spriel AB; Vermeulen H; Huls G; van Garderen E; van de Winkel JG
Cancer Res; 2001 May; 61(10):4055-60. PubMed ID: 11358825
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages.
Lohse S; Brunke C; Derer S; Peipp M; Boross P; Kellner C; Beyer T; Dechant M; van der Winkel JG; Leusen JH; Valerius T
J Biol Chem; 2012 Jul; 287(30):25139-50. PubMed ID: 22679018
[TBL] [Abstract][Full Text] [Related]
14. Anti-CD20 IgA can protect mice against lymphoma development: evaluation of the direct impact of IgA and cytotoxic effector recruitment on CD20 target cells.
Pascal V; Laffleur B; Debin A; Cuvillier A; van Egmond M; Drocourt D; Imbertie L; Pangault C; Tarte K; Tiraby G; Cogné M
Haematologica; 2012 Nov; 97(11):1686-94. PubMed ID: 22689689
[TBL] [Abstract][Full Text] [Related]
15. Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells.
Okita R; Shimizu K; Nojima Y; Yukawa T; Maeda A; Saisho S; Nakata M
Oncol Rep; 2015 Dec; 34(6):2864-70. PubMed ID: 26503698
[TBL] [Abstract][Full Text] [Related]
16. Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy.
Stockmeyer B; Dechant M; van Egmond M; Tutt AL; Sundarapandiyan K; Graziano RF; Repp R; Kalden JR; Gramatzki M; Glennie MJ; van de Winkel JG; Valerius T
J Immunol; 2000 Nov; 165(10):5954-61. PubMed ID: 11067958
[TBL] [Abstract][Full Text] [Related]
17. IgGA: a "cross-isotype" engineered human Fc antibody domain that displays both IgG-like and IgA-like effector functions.
Kelton W; Mehta N; Charab W; Lee J; Lee CH; Kojima T; Kang TH; Georgiou G
Chem Biol; 2014 Dec; 21(12):1603-9. PubMed ID: 25500223
[TBL] [Abstract][Full Text] [Related]
18. C-Reactive Protein Enhances IgG-Mediated Cellular Destruction Through IgG-Fc Receptors
Temming AR; Tammes Buirs M; Bentlage AEH; Treffers LW; Feringa H; de Taeye SW; Kuijpers TW; Nagelkerke SQ; Brasser G; Mok JY; van Esch WJE; van den Berg TK; Rispens T; van der Schoot CE; Vidarsson G
Front Immunol; 2021; 12():594773. PubMed ID: 33790888
[TBL] [Abstract][Full Text] [Related]
19. In Vitro and In Vivo Comparison of Lymphocytes Transduced with a Human CD16 or with a Chimeric Antigen Receptor Reveals Potential Off-Target Interactions due to the IgG2 CH2-CH3 CAR-Spacer.
Clémenceau B; Valsesia-Wittmann S; Jallas AC; Vivien R; Rousseau R; Marabelle A; Caux C; Vié H
J Immunol Res; 2015; 2015():482089. PubMed ID: 26665156
[TBL] [Abstract][Full Text] [Related]
20. Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting.
Meyer S; Nederend M; Jansen JH; Reiding KR; Jacobino SR; Meeldijk J; Bovenschen N; Wuhrer M; Valerius T; Ubink R; Boross P; Rouwendal G; Leusen JH
MAbs; 2016; 8(1):87-98. PubMed ID: 26466856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]